University of Southern California
USC Norris Comprehensive Cancer Center
If you are a patient, please contact Keck Medical Center of USC at 800-USC-CARE.

Trial Search: "Breast"



Treatment trials which apply specifically to your search:


0C-11-3

Trial Leaders:
Anthony El-Khoueiry

A First-In-Human Phase I Study of sEphB4-HSA in Patients with Advanced Solid Tumors with Expansion at the Maximum Tolerated Dose (MTD) or Recommended Phase II Dose (RP2D).

Treatment:
Anti-Angiogenesis

0C-13-4

Trial Leaders:
Heinz Josef Lenz

A Phase I, Open-Label, Multiple-Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Avelumab (MSB0010718C) in Subjects with Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications

Treatment:
Chemotherapy: Systemic

0C-13-8

Trial Leaders:
Heinz Josef Lenz

A Phase Ib/II Clinical Study of BBI608 Administered with Paclitaxel in Adult Patients with Advanced Malignancies

Treatment:
Chemotherapy: Systemic

0C-14-2

Trial Leaders:
David Quinn

An Open-Label, Phase 2 Study of Neratinib in Patients with Solid Tumors with Somatic Human Epidermal Growth Factor Receptor (Egfr, Her2, Her3) Mutations or EGFR Gene Amplification

Treatment:
Chemotherapy: Systemic

0R-14-2

Trial Leaders:
Eric Chang

Evaluation of Targeted Radiofrequency Ablation and Vertebral Augmentation prior to or following Radiation Therapy to Treat Painful Metastatic Vertebral Body Tumor(s)

Treatment:
Other

0S-08-9

Trial Leaders:
Tanya Dorff

Short-Term Fasting Prior to Platinum-Based Chemotherapy: Feasibility and Impact on Toxicity.

Treatment:
Chemotherapy: Systemic

0S-10-3

Trial Leaders:
Tanya Dorff

A Randomized, Phase II Clinical Trial of a Controlled Diet Prior to Selected Chemotherapy Treatment in Breast and Prostate Cancer to Evaluate the Impact on Toxicity and Efficacy.

Treatment:
Other

0S-14-9

Trial Leaders:
Heinz Josef Lenz

A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination with Nivolumab in Select Advanced Cancers

Treatment:
Chemotherapy: Systemic
Immunotherapy

0S-15-1

Trial Leaders:
Heinz Josef Lenz

A Multi-Center Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with MEDI4736, in Subjects with Relapsed or Refractory Solid Tumors

Treatment:
Chemotherapy: Systemic

1B-12-1

Trial Leaders:
Christina M. Dieli-Conwright

Combined Exercise Program for Early Breast Cancer Survivors.

Treatment:
(No treatments specified)

1B-12-10

Trial Leaders:
Darcy Spicer

Phase II Trial of Metronomic Capecitabine and Cyclophosphamide with Lapatinib and Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-Based Regimen.

Treatment:
Chemotherapy: Systemic
Immunomodulator

1B-13-1

Trial Leaders:
Christy Russell

A Phase II Study of Neratinib Alone and in Combination with Fulvestrant in Metastatic HER2 Non-amplified but HER2 Mutant Breast Cancer

Treatment:
Chemotherapy: Systemic

1B-13-10

Trial Leaders:
Darcy Spicer

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer. (The “METRIC” Study)

Treatment:
Chemotherapy: Systemic

1B-13-11

Trial Leaders:
Christy Russell

A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib versus Physician’s Choice In Previously-Treated, HER2 Negative, Germline BRCA Mutation-Positive Breast Cancer Patients (BRAVO)

Treatment:
Chemotherapy: Systemic

1B-14-5

Trial Leaders:
Christina M. Dieli-Conwright

High-intensity Interval training (HIT) for Breast Cancer Patients during Trastuzumab Use

Treatment:
Other

1B-14-7

Trial Leaders:
Heather R. Macdonald

Breast Cancer Patient Navigation and Tailored Treatment Planning: A Process Evaluation Study for LAC+USC Patient Navigation, Treatment Planning, and Ongoing Support for Latina Women

Treatment:
Other

ctsu/CALGB-A011202

Trial Leaders:
Heather R. Macdonald

A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (CT1-3 N1) who Have Positive Sentinel Lymph Node Disease after Neoadjuvant Chemotherapy

Treatment:
Radiation: External
Surgery

ctsu/NSABP-51/RTOG1304

Trial Leaders:
Eugene Chung

A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy

Treatment:
Radiation: External

NRG-BR001

Trial Leaders:
Eugene Chung

A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases

Treatment:
Radiation: External

SWOG-S1200

Trial Leaders:
Christy Russell

Randomized Blinded Sham- and Waitlist-Controlled Trial of Acupuncture for Joint Symptoms Related to Aromatase Inhibitors in Women with Early Stage Breast Cancer.

Treatment:
Other

SWOG-S1207

Trial Leaders:
Darcy Spicer

Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer.

Treatment:
Chemotherapy: Systemic
Hormone

Phase I trials for all solid tumors:


0C-11-1

Trial Leaders:
Heinz Josef Lenz

Phase I Pharmacokinetic Study of Belinostat for Solid Tumors and Lymphomas in Patients with Varying Degrees of Hepatic Dysfunction.

Treatment:
Chemotherapy: Systemic

0C-11-3

Trial Leaders:
Anthony El-Khoueiry

A First-In-Human Phase I Study of sEphB4-HSA in Patients with Advanced Solid Tumors with Expansion at the Maximum Tolerated Dose (MTD) or Recommended Phase II Dose (RP2D).

Treatment:
Anti-Angiogenesis

0C-12-3

Trial Leaders:
Heinz Josef Lenz

Phase I Trial of Oral 5-Fluoro-2’-Deoxycytidine With Oral Tetrahydrouridine in Patients With Advanced Solid Tumors.

Treatment:
Chemotherapy: Systemic

0C-13-1

Trial Leaders:
Anthony El-Khoueiry

An Open-Label, Parallel-Group, Multi-Center Phase I Study to Investigate the Pharmacokinetics of NKTR-102 for Injection (Etirinotecan Pegol) in Patients with Advanced or Metastatic Solid Tumors and Mild or Moderate Hepatic Impairment.

Treatment:
Chemotherapy: Systemic

0C-13-6

Trial Leaders:
Heinz Josef Lenz

A Phase 1, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability, and Pharmacokinetic Study of TAS-114 In Combination with Capecitabine in Patients with Advanced Solid Tumors

Treatment:
Chemotherapy: Systemic

0C-13-7

Trial Leaders:
Heinz Josef Lenz

A Phase 1b, Multi-Center, Non-Randomized, Open Label, Dose Escalation Design Study of Regorafenib (BAY 73-4506) in Combination with Cetuximab In Subjects with Locally Advanced or Metastatic Solid Tumors Who aren not Candidates for Standard Therapy or in Whom Regorafenib or Cetuximab is Considered as A Standard Treatment

Treatment:
Chemotherapy: Systemic

0C-14-10

Trial Leaders:
Anthony El-Khoueiry

A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 under Adaptable Dosing Schedules in Patients with Advanced Solid Malignancies

Treatment:
Chemotherapy: Local

0C-14-6

Trial Leaders:
David Quinn

A Phase I, Open-Label, Multi-Center, Dose Escalation Study of Oral BGJ398, a Pan FGF-R Kinase Inhibitor, in Adult Patients with Advanced Solid Malignancies

Treatment:
Immunotherapy

0C-14-9

Trial Leaders:
Anthony El-Khoueiry

A Modular Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD6738 in combination with Cytotoxic Chemotherapy and/or DNA Damage Repair/Novel Anti-cancer Agents in Patients with Advanced Solid Malignancies

Treatment:
Chemotherapy: Systemic

0S-08-9

Trial Leaders:
Tanya Dorff

Short-Term Fasting Prior to Platinum-Based Chemotherapy: Feasibility and Impact on Toxicity.

Treatment:
Chemotherapy: Systemic

0S-14-9

Trial Leaders:
Heinz Josef Lenz

A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination with Nivolumab in Select Advanced Cancers

Treatment:
Chemotherapy: Systemic
Immunotherapy

Trials which are NOT treatments of disease. Specimens or information may be collected:


0S-00-16

Trial Leaders:
Heinz Josef Lenz

Molecular Determinants of Response and Survival to Platinum Compounds (Oxaliplatin and Cisplatin) in Patients with Cancer.


0S-04-7

Trial Leaders:
Michael Press

USC Tumor and Tissue Bank.


0S-08-5

Trial Leaders:
Darcy Spicer

Multi-Center Database/Registry of Subjects at High Risk for Ovarian or Breast Cancer – A Lynne Cohen Consortium Project.


0S-10-1

Trial Leaders:
Florence Wong

A Survey of Complementary and Alternative Medicine (CAM) Use and Interest to Participate in CAM Research Studies in a Comprehensive Cancer Center.


0S-11-3

Trial Leaders:
Charite Ricker

Intervention to Promote Uptake of Cancer Risk Counseling for Underserved Latinas.


0S-11-5

Trial Leaders:
Amir Goldkorn

Circulating Tumor Cell Collection from Cancer Patients.


0S-12-4

Trial Leaders:
Stephen Gruber

USC Norris Comprehensive Cancer Center - Cancer Genetics Registry.


0S-13-1

Trial Leaders:
Gregory Idos

USC Norris Comprehensive Cancer Center and Stanford Cancer Institute Cancer Genetics Hereditary Cancer Panel Testing


0S-15-12

Trial Leaders:
Stephen Gruber

Norris ORIEN Total Cancer Care Protocol: A Lifetime Partnership with Patients.


0S-15-9

Trial Leaders:
Heinz Josef Lenz

PhI-78, Patient-Derived Models Tissue Procurement Protocol For The National Cancer Institute (NCI)


0S-16-2

Trial Leaders:
Jorge Nieva

Accelerometry to Optimize and Monitor Human Performance in Cancer Chemotherapy Outpatients


1B-11-1

Trial Leaders:
Julie Lang

Breast Cancer Blood Biorepository.


1B-12-4

Trial Leaders:
Marisa Perdomo

Screening for Musculoskeletal Impairments and Quality of Life in Individuals Post-Treatment for Breast Cancer.


1B-12-6

Trial Leaders:
Jaques Van Dam

Light-Scattering Spectroscopy for the Detection of Stage II-III Breast Cancer: A Pilot Study.


1B-12-9

Trial Leaders:
Darcy Spicer

An Observational Cohort Study of Treatment Patterns and Outcomes in Patients with Her2 Positive (Her2+) Metastatic Breast Cancer.


1B-13-2

Trial Leaders:
Julie Lang

Core Biopsies of Breast Tumor Tissue Repository.


1B-13-8

Trial Leaders:
Linda Hovanessian

Real Time Contrast Enhanced Ultrasound and Ultrasound-Based Elastography: Novel Techniques in Assessment of Treatment Response to Neoadjuvant Chemotherapy for Breast Cancer.


1B-14-6

Trial Leaders:
Anna Wu

Changes in Intestinal Microbiota in Association with Chemotherapy Treatment


1B-15-3

Trial Leaders:
Alexandra Sleight

Supportive Care Needs Of Breast Cancer Survivors At LAC+USC: A Cross-Sectional Survey


2N-12-7

Trial Leaders:
Daniel Oh

DNA Methylation Markers for Detecting Cancer Cells in Malignant Pleural Effusion.


3G-07-3

Trial Leaders:
Heinz Josef Lenz

Establishing Continuous Cell Lines and Xenografts from Adult Malignant Solid Tumors and Inflammatory Bowel Disease for Biological and Pre-Clinical Therapeutic Studies.


6CNS-07-1

Trial Leaders:
Thomas Chen

Establishment of USC CNS and Spine Tumor Bank.